PharmaShots

MARCH 27, 2023

follow-up Ref: Pharmiweb | Image: Bayer Related News:- Bayer’s Kerendia (finerenone) Receives Health Canada’s Approval for the Treatment of Chronic Kidney Disease and Type 2 Diabetes or death from renal causes by 18% (relative & absolute risk reduction 3.3%) over a median duration of follow-up of 2.6yrs.,

40

40

PharmaShots

JUNE 29, 2023

Shots: The P-I study evaluates the safety & tolerability of bemdaneprocel transplantation in patients (n=12) with Parkinson's disease 1yr. Shots: The P-I study evaluates the safety & tolerability of bemdaneprocel transplantation in patients (n=12) with Parkinson's disease 1yr.

40

40

PharmaShots

JUNE 28, 2023

Shots: The P-III (QUANTI) clinical trials evaluate the safety & efficacy of gadoquatrane (0.04mmol Gd/kg bw) vs GBCAs (0.1mmol Gd/kg) to be used in radio-imaging. The QUANTI study is composed of 2 P-III trials incl. Your go-to media platform for customized news ranging for multiple indications.

40

40

PharmaShots

JUNE 29, 2023

11 for 1-5yrs. 11 for 1-5yrs. & 10 for ≥5yrs. Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Adverse Reactions 40

Adverse Reactions 40

pharmaphorum

JULY 1, 2022

On the heels of approvals in the US, Europe and Japan, Bayer’s Kerendia for chronic kidney disease (CKD) associated with type 2 diabetes has been cleared for use in China, unlocking another big market for the drug. The post Bayer grabs Chinese okay for CKD therapy Kerendia appeared first on.

Labelling 52

Labelling 52

PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40

FDA 40

PharmD Live

DECEMBER 21, 2021

Virtual care a boon for underserved chronic care populations. Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. New Standard for Blood Pressure in Chronic Kidney Disease.

FDA 52

FDA Hospitals 52

pharmaphorum

AUGUST 8, 2022

Prostate cancer remains the second leading cancer-related cause of death among men in the US, with up to one-third of patients developing metastatic disease. Around 95% of prostate cancers are localised at diagnosis and treated with surgery or radiotherapy, but tend to relapse.

Chemotherapy 59

Chemotherapy FDA 59

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

FDA 40

FDA 40

pharmaphorum

DECEMBER 1, 2022

In another win for Bayer, the Scottish Medicines Consortium (SMC) has accepted the company’s chronic kidney disease (CKD) drug, Kerendia (finerenone), for the treatment of adults with CKD associated with type 2 diabetes (T2D) in NHS Scotland. 40%, and renal death by 18%.

Hospitals 59

Hospitals 59

PharmaShots

MAY 11, 2023

The collaboration will strengthen Bayer’s oncology development pipeline with the addition of targeted radiotherapeutics using Bicycle’s peptide-based technology Ref: Bayer | Image: Bayer Related News:- Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

40

40